ExodusPoint Capital Management LP Purchases Shares of 16,786 Atyr PHARMA INC (NASDAQ:ATYR)

ExodusPoint Capital Management LP purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 16,786 shares of the company’s stock, valued at approximately $61,000.

Several other large investors also recently modified their holdings of the stock. Alterna Wealth Management Inc. bought a new position in Atyr PHARMA during the fourth quarter worth $36,000. Victory Capital Management Inc. bought a new position in shares of Atyr PHARMA during the 4th quarter worth about $37,000. Raymond James Financial Inc. bought a new position in shares of Atyr PHARMA during the 4th quarter worth about $39,000. JPMorgan Chase & Co. increased its position in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Finally, Farther Finance Advisors LLC bought a new stake in Atyr PHARMA in the 4th quarter valued at about $88,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Trading Up 1.3 %

NASDAQ ATYR opened at $3.01 on Tuesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $3.44 and a 200 day simple moving average of $3.28. Atyr PHARMA INC has a 12 month low of $1.42 and a 12 month high of $4.66. The firm has a market capitalization of $267.47 million, a P/E ratio of -3.20 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.